Racecadotril Use in Acute Watery Diarrhea

Dosing Recommendations

Pediatric dosing: Administer racecadotril at 1.5 mg per kilogram of body weight orally every 8 hours (three times daily) for children ≥ 3 months old, used only after adequate oral rehydration therapy has been established. This recommendation is based on randomized trials showing modest benefit and is considered to have moderate-quality evidence. 1
Adult efficacy: Clinical data indicate that racecadotril reduces stool volume in adults with acute watery diarrhea, although pediatric‑focused guidelines do not specify an adult dosing regimen. Evidence derives from adult studies of comparable design to pediatric trials. 1

Geographic limitation: Racecadotril is not marketed or available in the United States and Canada, which severely restricts its practical use in these regions. 1
Guideline stance (IDSA): The Infectious Diseases Society of America (IDSA) notes that, while racecadotril can lower stool output, its unavailability in North America limits any formal recommendation for routine use. The guideline reflects limited‑to‑moderate quality evidence. 1

Antisecretory vs antimotility agents: Racecadotril is an antisecretory medication that does not affect intestinal motility and has a more favorable safety profile compared with antimotility agents such as loperamide. This distinction is emphasized in safety assessments. 1
Loperamide contraindication in children: Loperamide should never be used in individuals < 18 years because it has been linked to serious adverse events, including deaths. This safety warning is highlighted in the same source. 1

Do not postpone necessary diagnostics or antimicrobial therapy: While racecadotril may be added as an adjunct, clinicians must continue timely evaluation for signs of inflammatory or invasive diarrhea (e.g., blood, fever, systemic toxicity) and initiate appropriate antimicrobial treatment when indicated. 1

Racecadotril can be considered as adjunctive therapy to oral rehydration in acute watery diarrhea, particularly in regions where it is available, but current evidence does not support its routine use as it provides only modest clinical benefit compared to oral rehydration alone 2

Racecadotril is not available in North America, limiting its practical application in the United States and Canada 2, 3, 4

Racecadotril has demonstrated efficacy in reducing stool volume in adults with acute diarrhea and should only be considered after adequate hydration is achieved 2, 3
The primary treatment for acute diarrhea remains oral rehydration therapy, with racecadotril being only an adjunct 2, 3

Racecadotril should be used when a patient has acute watery diarrhea, adequate hydration has been established, the drug is available in the geographic region, and the patient is ≥3 months of age 2, 3
Racecadotril should not be used when a patient has inflammatory diarrhea, adequate oral rehydration has not been initiated, or in North America where the drug is unavailable 2, 3